{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-TIGIT",
    "query": {
      "intervention": "Anti-TIGIT"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 36,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-TIGIT&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-17T22:52:09.112Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04952597",
      "title": "Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Limited Stage Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Ociperlimab",
          "type": "DRUG"
        },
        {
          "name": "Tislelizumab",
          "type": "DRUG"
        },
        {
          "name": "Concurrent Chemoradiotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BeiGene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 126,
      "start_date": "2021-07-15",
      "completion_date": "2023-07-26",
      "has_results": true,
      "last_update_posted_date": "2024-10-26",
      "last_synced_at": "2026-09-17T22:52:09.112Z",
      "location_count": 1,
      "location_summary": "Knoxville, Tennessee",
      "locations": [
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04952597"
    },
    {
      "nct_id": "NCT04995523",
      "title": "A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Small-Cell Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "AZD2936",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 212,
      "start_date": "2021-09-14",
      "completion_date": "2028-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-09-17T22:52:09.112Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Rochester, Minnesota • Fairfax, Virginia",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04995523"
    },
    {
      "nct_id": "NCT03739710",
      "title": "Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Feladilimab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "GSK4428859A",
          "type": "DRUG"
        },
        {
          "name": "Dostarlimab",
          "type": "DRUG"
        },
        {
          "name": "GSK6097608",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 175,
      "start_date": "2019-01-24",
      "completion_date": "2024-05-02",
      "has_results": true,
      "last_update_posted_date": "2025-06-15",
      "last_synced_at": "2026-09-17T22:52:09.112Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • St Louis, Missouri • The Bronx, New York + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Pinehurst",
          "state": "North Carolina"
        },
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03739710"
    },
    {
      "nct_id": "NCT04256421",
      "title": "A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Tiragolumab",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 490,
      "start_date": "2020-02-04",
      "completion_date": "2025-07-31",
      "has_results": true,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-09-17T22:52:09.112Z",
      "location_count": 18,
      "location_summary": "Lone Tree, Colorado • Washington D.C., District of Columbia • Fort Myers, Florida + 15 more",
      "locations": [
        {
          "city": "Lone Tree",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04256421"
    },
    {
      "nct_id": "NCT06989112",
      "title": "DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "Trastuzumab deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Rilvegostomig",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 600,
      "start_date": "2025-03-27",
      "completion_date": "2031-02-19",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-09-17T22:52:09.112Z",
      "location_count": 61,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 55 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06989112"
    },
    {
      "nct_id": "NCT04262856",
      "title": "Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Nonsquamous Non Small Cell Lung Cancer",
        "Squamous Non Small Cell Lung Cancer",
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Domvanalimab",
          "type": "DRUG"
        },
        {
          "name": "Etrumadenant",
          "type": "DRUG"
        },
        {
          "name": "Zimberelimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arcus Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 151,
      "start_date": "2020-05-28",
      "completion_date": "2025-07-09",
      "has_results": false,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-09-17T22:52:09.112Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Whittier, California • Englewood, Florida + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tallahassee",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04262856"
    },
    {
      "nct_id": "NCT06754501",
      "title": "A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Tiragolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2025-04-11",
      "completion_date": "2029-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-18",
      "last_synced_at": "2026-09-17T22:52:09.112Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06754501"
    },
    {
      "nct_id": "NCT04656535",
      "title": "AB154 Combined With AB122 for Recurrent Glioblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Zimberelimab",
          "type": "DRUG"
        },
        {
          "name": "Domvanalimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2021-04-21",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-09-17T22:52:09.112Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • New Haven, Connecticut • Boston, Massachusetts",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04656535"
    },
    {
      "nct_id": "NCT03119428",
      "title": "A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced Cancer",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "OMP-313M32",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OncoMed Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2017-05-02",
      "completion_date": "2019-05-15",
      "has_results": false,
      "last_update_posted_date": "2020-08-11",
      "last_synced_at": "2026-09-17T22:52:09.112Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Durham, North Carolina • Oklahoma City, Oklahoma + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03119428"
    },
    {
      "nct_id": "NCT05060432",
      "title": "Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Cancer",
        "Lung Cancer",
        "Head and Neck Cancer",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "EOS-448",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "inupadenant",
          "type": "DRUG"
        },
        {
          "name": "Dostarlimab",
          "type": "DRUG"
        },
        {
          "name": "SOC chemotherapies",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "iTeos Belgium SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 153,
      "start_date": "2021-09-06",
      "completion_date": "2025-07",
      "has_results": false,
      "last_update_posted_date": "2024-06-21",
      "last_synced_at": "2026-09-17T22:52:09.112Z",
      "location_count": 2,
      "location_summary": "San Diego, California • Bergen, New Jersey",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Bergen",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05060432"
    }
  ]
}